Nivo-Ipi More Effective, More Toxic Than Anti-PD-1 Monotherapy in High-Risk Melanoma
Source: Cancer Therapy Advisor, March 2024
Neoadjuvant treatment with nivolumab and ipilimumab (nivo-ipi) is more effective but more toxic than anti-PD1 monotherapy for patients with high-risk, resectable melanoma, according to research published in JAMA Oncology.
Researchers pooled data from 6 trials and found that patients who received nivo-ipi were more likely to achieve pathologic complete responses, but these patients also had a greater risk of grade 3-4 immune-related adverse events (irAEs).
This analysis included 573 patients with high-risk, resectable melanoma who received immune checkpoint inhibitors on phase 1-3 trials. In 4 trials, patients received nivo-ipi. In 2 trials, patients received pembrolizumab alone or nivolumab alone.